
Lucet to Acquire Home Care Company Emcara Health
Lucet, a behavioral health company, is acquiring home care company Emcara Health to offer integrated care models.
Lucet, a behavioral health company, is acquiring home care company Emcara Health to offer integrated care models.
Two hospital-at-home providers, DispatchHealth and Medically Home, announced their plan to merge. Once combined, the company will provide in-home care across 50 major metropolitan areas and partner with nearly 40 health systems.
Transcarent is planning to acquire Accolade for $621 million, the companies announced Wednesday. The two companies are very complementary and the deal gives Accolade a chance to turn things around after struggling in the public market, experts say.
Belgian sleep diagnostics company Sunrise announced the acquisition of Dreem Health, a California-based sleep clinic. This has allowed Sunrise to provide its telehealth-based sleep care in California, Iowa, Maryland and Washington, with plans to be available nationwide next year.
Perelel has acquired LOOM, an educational platform for reproductive health, sexual wellness and parenting. Through the acquisition, the company aims to advance health literacy for women.
Novant Health called off its planned $320 million acquisition of two CHS-owned hospitals in North Carolina. The decision came after an appellate court granted the FTC an emergency injunction to block the deal — the agency had been challenging the deal for more than a year.
Break down the silos. Take control of your provider data.
Knownwell acquired one of its competitors, just six months after announcing its $20 million Series A funding round. The startup, which provides hybrid primary care and metabolic health treatment, bought Alfie Health, an online obesity management clinic with an AI platform that generates personalized recommendations for weight management.
Centivo, a health plan that sells to self-funded employers, acquired virtual-first primary care startup Eden Health. With this acquisition, Centivo now serves more than 160 employers in all 50 states.
Novo Holdings’ $16.5 billion planned acquisition of Catalent is facing another delay. Just weeks after Novo decided to resubmit its application to the FTC, the agency is seeking more information about the deal. This move has triggered a second 30-day delay in the antitrust review process.
WebMD acquired the operating assets of Healthwise, a nonprofit provider of health education content and patient engagement tools. The deal follows another acquisition WebMD made in the patient engagement space in 2020. According to Ann Bilyew, WebMD’s senior vice president of health, the company is now “the indisputable market leader in providing patient education to both providers and payers.”
General Catalyst just announced its plans to acquire Summa Health, an Ohio-based health system. Leaders from across the healthcare industry aren't sure how the deal will play out, given the novel nature of the deal and the involvement of one of the country’s most prominent VC firms.
Innovaccer acquired Cured, a healthcare digital marketing and CRM platform. With the deal, Innovaccer gains more than 20 customers to add to its current portfolio of clients. Innovaccer CEO Abhinav Shashank said the main goal of the acquisition was to help his company become a leader in patient experience technology.
Guidehealth, a nascent value-based care enablement startup, acquired Arcadia’s value-based care service division. Acquiring this business unit allows Guidehealth to provide health systems with a platform that helps them succeed in value-based care arrangements while still maintaining their patient volume levels.
AbbVie announced plans to acquire Immunogen — and the biotech’s recently approved ADC treatment for ovarian cancer — for $10.1 billion in cash. The pharma giant is diving into ADCs again after a previous multibillion-dollar acquisition of a different ADC drugmaker ended up failing a few years ago.
Acquiring Point Biopharma gives Eli Lilly a pipeline of radiopharmaceuticals, including one for prostate cancer that could rival Novartis’s Pluvicto. The deal comes ahead of an expected Phase 3 data readout for that Point therapeutic candidate.